The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | CCTX-001: a novel CAR-T therapy for AML
Nicolas Boissel, MD, PhD, Saint-Louis Hospital, Paris, France, discusses the novel CAR-T product CCTX-001, which has shown promising preclinical efficacy against an antigen specific to acute myeloid leukemia (AML). This product is planned to be trialed in a Phase I study at the end of this year. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
